about
B-Raf and the inhibitors: from bench to bedsideThe regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionThe biology of the Ets1 proto-oncogeneReleasing the brake: targeting Cbl-b to enhance lymphocyte effector functionsThe neurobiology of cocaine addictionDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsTet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNATargeting BRAF in thyroid cancerBHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reportsBalancing Akt with S6K: implications for both metabolic diseases and tumorigenesisThe cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.Cyclin D1 and mammary carcinoma: new insights from transgenic mouse modelsSignaling through Raf-1 in the neovasculature and target validation by nanoparticlesMolecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis.Wnt signaling in breast cancer: have we come full circle?Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting.Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatmentUpdate on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.The WntsA new model for ductal carcinoma in situ suggests strategies for treatmentTyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinasesp27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosisMultiple Functions of Ten-eleven Translocation 1 during TumorigenesisFGFR3-TACC3 fusion in solid tumors: mini reviewThe importance of ribosome production, and the 5S RNP-MDM2 pathway, in health and diseaseThe Philadelphia chromosome in leukemogenesisDeep molecular responses for treatment-free remission in chronic myeloid leukemiaFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-AnalysisOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibKirsten Ras* oncogene: Significance of its discovery in human cancer researchBiomarker development in MET-targeted therapyThe RNA helicase A in malignant transformationThe Significance of Ras Activity in Pancreatic Cancer InitiationRetargeting Strategies for Oncolytic Herpes Simplex VirusesBreast cancer survival among young women: a review of the role of modifiable lifestyle factorsPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaG-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT SignalingInsights into Coupled Folding and Binding Mechanisms from Kinetic StudiesTherapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
P921
Q21198860-BADE8FC9-0D59-4885-9DDC-A2A83FCE5C69Q21245733-D96EB5C2-FDFA-4D0E-B939-89498AE7EF11Q21245748-7FA2D3E2-1D4B-4476-B328-32C8E4B5B956Q21285001-C7D6680C-B941-4EA9-AB3E-A3BAE14659F3Q24602314-1ACB586E-F7E3-403E-AEF2-9A351BA0D6BBQ24617091-9FF4CC85-8D54-4195-8FAC-7953FC2BABCCQ24632387-e993ef41-4606-9f9a-593a-b14802875ed4Q24653496-28463D71-559F-488F-B112-F4FF3CF4D64FQ24654382-15BAE297-42E7-4D50-84E2-2C5301659FBFQ24676203-3DC82CE2-265F-45F6-9D38-2CAE44EE3FCFQ24793380-1D8E1744-4C44-44B6-B1A3-DEC2E031C4DDQ24796232-50C05833-FA29-4B73-9163-10628A7A9630Q24798542-B98DEFB9-13AB-45B1-9242-76CFCA98303DQ24800958-3204163B-2DB9-408A-AE9A-A502AE245D95Q24801811-85FB8595-8E9C-4140-8EC1-43D5E6FE71A8Q24801924-60836BF7-1102-4CC4-B1CC-76780D675C8BQ24801967-434E32EC-29FC-4958-AD15-D352DD396DAEQ24801995-268E8F4D-3ABA-434F-826E-1DBBFA0D94C4Q24802301-C99C6347-71EF-4CB2-9404-3D1D4CFB87CDQ24802734-7A47EF22-8326-4654-A70C-C3E75834A3BFQ24802950-14C9BEF8-E801-40B0-8EB4-4344B852DFC0Q24803633-24E0531E-4FAC-4796-B295-83426F62A7ACQ26740522-CC43E689-6D46-4A9D-8597-A701E26127BBQ26740578-AE0ADE76-73D5-4152-8E6F-53F52AD61F5EQ26741340-16BEDC66-61A2-402A-89B9-E3F12D15205BQ26745531-30995A4A-AC8C-4FB8-974A-E3CDEA00011AQ26745594-AA65EAC0-091A-4998-B5EF-5EA3D1EF14AAQ26746081-279EB183-D398-43ED-A5A5-F8E7A3D1E410Q26749186-9EB3A8A1-91F3-4044-A520-509735966CA1Q26750696-AB9FA565-9936-47B0-B68A-48552AC91FF2Q26751212-7C956BF8-E065-41E0-B4DF-C2DB3115D4BBQ26751332-C9377875-3CE6-4128-AAB5-7FCE24574F8BQ26765181-83F128B5-3082-463D-A942-3C229E05B411Q26765230-DCC85972-1B7C-4E05-871F-6C1820FBB7C1Q26765439-A68908C9-BC32-4DAB-B616-779642B81488Q26766205-B85C01A2-5435-4C91-83EF-683D2A0F5C4EQ26766293-06D6DA9A-5071-4ED8-8523-2E63A3FAB793Q26767279-07D63610-4838-4F00-A5C2-6EDE78A2FFF2Q26768540-D1DE255B-9262-4FAE-BABF-E02D8C665FCFQ26768602-4256ADAA-033B-4909-A4B5-CBCCD9F92F3B
P921
description
products of proto-oncogenes
@en
name
proto-oncogene proteins
@en
type
label
proto-oncogene proteins
@en
altLabel
proto-oncogene protein
@en
prefLabel
proto-oncogene proteins
@en
P486
P279
P486
P672
D12.776.624.664.700